Entering text into the input field will update the search result below

Evogene's Canonic Positioned To Enter Israeli Medical Cannabis Market

Apr. 07, 2021 1:05 PM ETEvogene Ltd. (EVGN)6 Comments
Alan Sumler profile picture
Alan Sumler


  • Canonic, a subsidiary of Evogene, has a strategy to enter the Israeli medical cannabis market.
  • Canonic, using Evogene’s CPB platform, is developing innovative cannabis strains to meet industry needs.
  • Evogene operates at a Net Loss but has assets, cash, and no debt.
  • Evogene’s stock has been on a one-year uptrend at 384% with break-out rallies.
  • I recommend a long-hold strategy with a potential for 25% to 40% profit.

As pure as the green stuff gets
Photo by Marco VDM/E+ via Getty Images

Evogene (NASDAQ:EVGN) is the parent company to four subsidiaries, Biomica, agPlenus, Canonic, and Lavie Bio. Each company uses Evogene’s Artificial Intelligence engine, the CPB platform

This article was written by

Alan Sumler profile picture
Welcome to the home of The Cannabis Report: a monthly report on the cannabis industry. I am an analyst and consultant in the cannabis industry. I have contributed to High Times Magazine. I currently have a book out, Cannabis in the Ancient Greek and Roman World. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about the cannabis industry or publicly traded stocks in the cannabis industry.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in EVGN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

jsiebel720 profile picture
Because of Cathy Wood's holding EVGN in her funds, it's been a roller coaster ride, double-edged sword for the stock price. Hopefully, this will end going forward with today's earning report for Q1
@Alan Sumler

any comment on sell off...keep going down every week
Alan Sumler profile picture
@Dinesh S I am continuing to hold this stock.It has some time before it matures.
@Alan Sumler
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2021 on Wednesday, May 26th, 2021. Mr. Ido Dor, Chief Executive Officer of Evogene's subsidiary, Lavie Bio Ltd., will join the conference call to discuss Lavie Bio's recent activity.
Getting in, I love teeny companies...what can go wrong?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About EVGN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on EVGN

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.